Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab : A Report of Two Cases
© 2021 The Japan Neurosurgical Society..
"Diffuse midline glioma (DMG), H3K27M-mutant" was newly classified in the revised World Health Organization (WHO) 2016 classification of central nervous system tumors. Spinal cord DMG, H3K27M-mutant is relatively rare, with poor prognosis, and there are no effective treatment protocols. In this study, we report two cases of spinal cord DMG, H3K27M-mutant treated with bevacizumab. The two patients were women in their 40s who initially presented with sensory impairment. MRI showed spinal intramedullary tumors, and each patient underwent laminectomy/laminoplasty and biopsy of the tumors. Histological examination initially suggested low-grade astrocytoma in case 1 and glioblastoma in case 2. Upon further immunohistochemical examination in case 1 and molecular examination in case 2, however, both cases were diagnosed as DMG, H3K27M-mutant. Case 1 was treated with radiation therapy and temozolomide (TMZ) chemotherapy, which induced a transient improvement of symptoms; 3 months after surgery, however, the patient's symptoms rapidly deteriorated. MRI showed tumor enlargement with edema to the medulla. Triweekly administration of bevacizumab improved her symptoms for the following 12 months. Case 2 was treated with bevacizumab from the beginning because of acute deterioration of breathing. After bevacizumab administration, both cases showed tumor regression on MRI and drastic improvement of symptoms within a few days. Although spinal cord DMG, H3K27M-mutant has an aggressive clinical course and poor prognosis, bevacizumab administration may offer the significant clinical benefit of alleviating edema, which improves patient's capacity for activities of daily life.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
NMC case report journal - 8(2021), 1 vom: 01., Seite 505-511 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yabuno, Satoru [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 27.01.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2176/nmccrj.cr.2021-0033 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336139357 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336139357 | ||
| 003 | DE-627 | ||
| 005 | 20231225231447.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2176/nmccrj.cr.2021-0033 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1120.xml |
| 035 | |a (DE-627)NLM336139357 | ||
| 035 | |a (NLM)35079510 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yabuno, Satoru |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spinal Cord Diffuse Midline Glioma, H3K27M- mutant Effectively Treated with Bevacizumab |b A Report of Two Cases |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.01.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Japan Neurosurgical Society. | ||
| 520 | |a "Diffuse midline glioma (DMG), H3K27M-mutant" was newly classified in the revised World Health Organization (WHO) 2016 classification of central nervous system tumors. Spinal cord DMG, H3K27M-mutant is relatively rare, with poor prognosis, and there are no effective treatment protocols. In this study, we report two cases of spinal cord DMG, H3K27M-mutant treated with bevacizumab. The two patients were women in their 40s who initially presented with sensory impairment. MRI showed spinal intramedullary tumors, and each patient underwent laminectomy/laminoplasty and biopsy of the tumors. Histological examination initially suggested low-grade astrocytoma in case 1 and glioblastoma in case 2. Upon further immunohistochemical examination in case 1 and molecular examination in case 2, however, both cases were diagnosed as DMG, H3K27M-mutant. Case 1 was treated with radiation therapy and temozolomide (TMZ) chemotherapy, which induced a transient improvement of symptoms; 3 months after surgery, however, the patient's symptoms rapidly deteriorated. MRI showed tumor enlargement with edema to the medulla. Triweekly administration of bevacizumab improved her symptoms for the following 12 months. Case 2 was treated with bevacizumab from the beginning because of acute deterioration of breathing. After bevacizumab administration, both cases showed tumor regression on MRI and drastic improvement of symptoms within a few days. Although spinal cord DMG, H3K27M-mutant has an aggressive clinical course and poor prognosis, bevacizumab administration may offer the significant clinical benefit of alleviating edema, which improves patient's capacity for activities of daily life | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a H3K27M | |
| 650 | 4 | |a bevacizumab | |
| 650 | 4 | |a diffuse midline glioma | |
| 700 | 1 | |a Kawauchi, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Umakoshi, Michiari |e verfasserin |4 aut | |
| 700 | 1 | |a Uneda, Atsuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Fujii, Kentaro |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Joji |e verfasserin |4 aut | |
| 700 | 1 | |a Otani, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hattori, Yasuhiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuboi, Nobushige |e verfasserin |4 aut | |
| 700 | 1 | |a Kohno, Shohei |e verfasserin |4 aut | |
| 700 | 1 | |a Noujima, Mai |e verfasserin |4 aut | |
| 700 | 1 | |a Toji, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yanai, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuhara, Takao |e verfasserin |4 aut | |
| 700 | 1 | |a Date, Isao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NMC case report journal |d 2014 |g 8(2021), 1 vom: 01., Seite 505-511 |w (DE-627)NLM273412310 |x 2188-4226 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:1 |g day:01 |g pages:505-511 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2176/nmccrj.cr.2021-0033 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 1 |b 01 |h 505-511 | ||